Feature | August 28, 2013

Cardiovascular Imaging Protocols for Cancer Patients Announced

August 28, 2013 — Experts have found that radiation dosage can have serious complications for patients with cancer. Cancer patients who receive chest radiation should be evaluated for heart disease before beginning radiation, and every five to 10 years afterward, according to the American Society of Echocardiography (ASE) and the European Assn. of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC). This expert consensus statement on the use of imaging to detect radiation-induced heart disease (RIHD) will be published in the September issue of the Journal of the American Society of Echocardiography (JASE). The writing group was co-chaired by Vuyisile Nkomo, M.D., an echocardiographer from the renowned Mayo Clinic in Rochester, Minn.

When asked about the need for this expert consensus statement, Nkomo said, “In the past, patients received high doses of radiation to the chest to treat breast cancer or lymphoma or esophageal cancer, but without adequate shielding of the heart because we did not know that radiation exposure would lead to premature heart disease. Over the years, the medical community has learned that patients with prior radiation to the chest develop premature heart disease that can involve all structures of the heart, leading to coronary artery disease, myocardial disease, valve disease, conduction system disease and pericardial disease.”

Nkomo continued, “Now that heart disease is a known delayed complication of radiation therapy, the guidelines were written to draw attention to this issue of radiation-induced heart disease (RIHD). And, it is urgent to get this information out and into clinical practice because of the increasing number of cancer survivors who receive radiation therapy to the chest and neck. Echocardiographic screening without indication of cardiovascular disease should not be a common practice in the general patient population, but assessments should be incorporated routinely in the initial care and follow-up of these cancer patients.” This guideline makes recommendations regarding when and how to look for RIHD, and it highlights the complementary nature of the various imaging modalities.

RIHD is estimated to occur in 10-30 percent of patients who receive chest radiotherapy within five to 10 years post-treatment. Modern treatment regimens incorporate lower radiation doses and improved shielding of the heart, but heart disease can still occur. In fact, Nkomo noted, “the improved safety of current treatment therapies means that RIHD may develop at widely varying rates among different populations. Therefore, data demonstrating temporal changes in incidence of RIHD and outcomes in the contemporary era are still needed.”

The full guideline document will be available on the Journal of American Society of Echocardiography (JASE) website (www.onlinejase.com) on Sept. 3, and will be published in the September 2013 print issue.

For more information: www.asecho.org/guidelines

 

 

Related Content

GE Healthcare, Vivid iq portable cardiovascular ultrasound, RSNA 2016, launch
Technology | Cardiovascular Ultrasound| September 22, 2016
September 22, 2016 — GE Healthcare announced the global commercial launch of its new generation of high-end portable
Toshiba, Aplio 500 Platinum ultrasound, International Contrast Ultrasound Society, ICUS, live case, contrast-enhanced ultrasound
News | Ultrasound Imaging| September 07, 2016
September 7, 2016 — Toshiba America Medical Systems Inc.
best ultrasound technician schools, 2016 ranking, College Choice
News | Ultrasound Imaging| August 22, 2016
August 22, 2016 — College Choice, a leading authority in college and university rankings and resources, has published
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
ASE, SCCT, SCMR, guideline, multimodality imaging, transposition of the great arteries, TGA
News | Congenital Heart| July 20, 2016
At the end of June, experts from three different medical societies released a new guideline to help optimize lifetime...
ContextVision, US PLUSView ultrasound enhancement software, iOS
Technology | Ultrasound Imaging| July 11, 2016
ContextVision has signed a contract to bring its US PLUSView ultrasound image enhancement software to hand-held iOS-...
Csound, GE ultrasound, cSound, Mitral valve, cardiac ultrasound

An example of improved cardiac ultrasound image processing using the GE cSound technology, which can create CT-like quality 3-D renderings of the anatomy.

Feature | Cardiovascular Ultrasound| July 11, 2016 | Jon Brubaker, MBA, RCVT and Sabrina Newell MS, RCS
There were several overall key trends evident at the 2016 meeting of the American Society of Echocardiography in June
ASE 2016, echo, echocardiography, cardiac ultrasound, annual meeting, ASE.16, American Society of Echocardiography
Feature | Cardiovascular Ultrasound| July 01, 2016
Below is a round up of news and videos about new cardiac ultrasound technology discussed in sessions and on the expo
Sponsored Content | Videos | Structural Heart| June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
Overlay Init